文献速递慢性肾脏病血液净化与透析

滤过标志物变化与终末期肾病及死亡风险

Risk of ESRD and Mortality Associated With Change in Filtration Markers.
PubMed 文献 · Am J Kidney Dis · 2017-06-23

该研究基于MDRD和AASK两项临床试验的观察性分析,评估血清肌酐、胱抑素C、β-痕迹蛋白和β2-微球蛋白估算的肾小球滤过率下降与ESRD及全因死亡风险的关系。结果显示mGFR、eGFRcr、eGFRBTP及四种标志物平均值下降均与ESRD风险增加显著相关,仅eGFRcr下降与AASK研究中全因死亡风险相关。

要点

  • mGFR、eGFRcr、eGFRBTP及四种标志物平均值的1年下降均与ESRD风险增加显著相关。
  • 仅eGFRBTP下降较mGFR下降与ESRD风险的关联更强,两项研究均显著。
  • eGFRcr下降与AASK研究全因死亡风险相关,但与mGFR下降的关联无显著差异。

核心结论

  • mGFR、eGFRcr、eGFRBTP及四种滤过标志物平均值的下降均与ESRD进展一致相关。
  • 仅eGFRcr下降与AASK研究全因死亡风险显著相关,但与其他标志物无显著差异。

研究设计与样本

  • 对MDRD研究(n=317)和AASK研究(n=373)两项临床试验的观察性分析。
  • 在12个月和24个月随访时测量血清肌酐、胱抑素C、BTP、B2M及mGFR。
  • 采用Poisson回归估计每30%下降的ESRD和全因死亡发生率比及95%CI,随访10-16年。

主要发现

  • mGFR、eGFRcr、eGFRBTP及四种标志物平均值的1年下降与ESRD风险增加显著相关(均P≤0.02)。
  • 与mGFR相比,仅eGFRBTP下降与ESRD风险的关联更强(均P≤0.03)。
  • eGFRcr下降与AASK研究全因死亡风险相关(每30%下降IRR=4.17,95%CI 1.78-9.74,P<0.001),但与mGFR下降的关联无显著差异(P=0.2)。

关键数值与推荐

  • 每30%下降的ESRD风险:mGFR、eGFRcr、eGFRBTP及四种标志物平均值均显著(P≤0.02)。
  • eGFRBTP下降与ESRD风险关联强于mGFR(P≤0.03)。
  • eGFRcr下降与AASK全因死亡:IRR=4.17(95%CI 1.78-9.74,P<0.001)。

临床怎么用

  • 在CKD人群中,eGFRcr、eGFRBTP及多标志物平均值的下降可用于评估ESRD进展风险。
  • eGFRcr下降与全因死亡风险的关联需谨慎解读,尤其在不同人群中。

局限性

  • 样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Using change in estimated glomerular filtration rate (eGFR) based on creatinine concentration as a surrogate outcome in clinical trials of chronic kidney disease has been proposed. Risk for end-stage renal disease (ESRD) and all-cause mortality associated with change in concentrations of other filtration markers has not been studied in chronic kidney disease populations. STUDY DESIGN: Observational analysis of 2 clinical trials. SETTING & PARTICIPANTS: Participants in the MDRD (Modification of Diet in Renal Disease; n=317) Study and AASK (African American Study of Kidney Disease and Hypertension; n=373). PREDICTORS: Creatinine, cystatin C, β-trace protein (BTP), and β2-microglobulin (B2M) were measured in serum samples collected at the 12- and 24-month follow-up visits, along with measured GFR (mGFR) at these time points. OUTCOMES: ESRD and all-cause mortality. MEASUREMENTS: Poisson regression was used to estimate incidence rate ratios and 95% CIs for ESRD and all-cause mortality during long-term follow-up (10-16 years) per 30% decline in mGFR or eGFR for each filtration marker and the average of all 4 markers. RESULTS: 1-year decline in mGFR, eGFRcr, eGFRBTP, and the average of the 4 filtration markers was significantly associated with increased risk for incident ESRD in both studies (all P≤0.02). Compared to mGFR, only decline in eGFRBTP was statistically significantly more strongly associated with ESRD risk in both studies (both P≤0.03). Decline in eGFRcr, but not mGFR or the other filtration markers, was significantly associated with risk for all-cause mortality in AASK only (incidence rate ratio per 30% decline, 4.17; 95% CI, 1.78-9.74; P<0.001), but this association was not significantly different from decline in mGFR (P=0.2). LIMITATIONS: Small sample size. CONCLUSIONS: Declines in mGFR, eGFRcr, eGFRBTP, and the average of 4 filtration markers (creatinine, cystatin C, BTP, and B2M) were consistently associated with progression to ESRD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Rebholz CM, Inker LA, Chen Y, et al. Risk of ESRD and Mortality Associated With Change in Filtration Markers. Am J Kidney Dis. 2017. PMID: 28648303. doi:10.1053/j.ajkd.2017.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。